All In Biotech

Drug Trial Radar · NCT06372652

A Phase 1 Study of TE-8214 Solution in Healthy Volunteers

A Randomized, Double-blinded, Placebo-controlled Phase 1 Study of a Single Dose of a Subcutaneous Ultra-Long-Acting Somatostatin Analog (TE-8214 Solution) to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jun 18, 2024

Primary completion

Oct 10, 2024

Study completion Dec 6, 2024

Sponsor

Lead sponsor
Immunwork, Inc.Industry
Sponsor type
Industry
First posted
Apr 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, first-in-human, randomized, double-blinded, placebo-controlled study to evaluate the safety, tolerability, and PK of TE-8214 in healthy volunteers. The study will assess single ascending doses (SAD) of TE-8214.

Conditions

  • Acromegaly

Interventions

  • TE-8214 - SADDrug

    Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg

  • PlaceboDrug

    Single subcutaneous dose of matching placebo across the cohorts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of TE-8214 by the incidence of treatment-emergent adverse events (TEAEs)Time frame: From administration of IP on Day 1 until the EOS/ET visit (Day 84) post dose
  2. Safety and tolerability of TE-8214 by the incidence of treatment-related adverse eventsTime frame: From screening until the EOS/ET visit (Day 84) post dose
  3. Safety and tolerability of TE-8214 by the incidence of injection site reactions (ISRs)Time frame: On Day 1, 0 hour, 6 hours, 12 hours, 24 hours, 48 hours,72 hours, 96 hours, 168 hours post dose
  4. Safety and tolerability of TE-8214 by the incidence of clinically significant laboratory findingsTime frame: From Screening until EOS/ET (Day 84) post dose
  5. Safety and tolerability of TE-8214 by the changes in physical examination findingsTime frame: At Screening, Day -1, Day 2, Day 8, Day 28, Day 56, Day 84 post dose
  6. Safety and tolerability of TE-8214 by the changes in ECG findingsTime frame: At Screening, Day -1, Day 1, Day 2, Day 4, Day 8, Day 14, Day 28, Day 56, Day 84 post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.